Skip to main content
. Author manuscript; available in PMC: 2007 Jul 6.
Published in final edited form as: Bone Marrow Transplant. 2006 Sep 4;38(8):539–546. doi: 10.1038/sj.bmt.1705488

Figure 1.

Figure 1

Time-to-event plots showing the absolute risk for development of extensive chronic graft-versus-host disease in the patients with hematologic malignancies who received four doses (a) or three doses (b) of MTX. There is more chronic GVHD of any stage in patients treated with allogeneic PBSC regardless of the MTX doses.